Aquestive Therapeutics (AQST) EBIT Margin (2017 - 2026)

Aquestive Therapeutics has reported EBIT Margin for 10 years, with the latest figure at 59.51% in Q2 2026.

• On a quarterly basis, EBIT Margin rose 5414.0% year-over-year to 59.51% in Q2 2026; TTM through Jun 2026 was 97.52%, a 2167.0% increase from a year earlier, with the FY2025 full-year figure at 159.5%, down 10605.0% from the prior year.
• EBIT Margin was 59.51% for Q2 2026 at Aquestive Therapeutics, down from 29.1% in the prior quarter.
• The five-year high for EBIT Margin was 0.27% in Q2 2024, with the low at 222.08% in Q1 2025.
• Average EBIT Margin over 5 years is 81.08%, with a median of 75.77% recorded in 2022.
• The sharpest annual moves came in 2025 and 2026: EBIT Margin tumbled 14776 bps in 2025, then surged 19297 bps in 2026.
• Over 5 years, EBIT Margin stood at 100.29% in 2022, then soared by 70 bps to 29.62% in 2023, then slumped by 286 bps to 114.43% in 2024, then sank by 94 bps to 221.58% in 2025, then jumped by 73 bps to 59.51% in 2026.
• The last three EBIT Margin figures came in at 59.51% (Q2 2026), 29.1% (Q1 2026), and 221.58% (Q4 2025), per Business Quant data.